BusinessHemispherx Biopharma Repurposes Ampligen in Immuno-OncologyBy Nasdaq OMXMay 31, 2017, 4:04 PM UTC
BusinessHemispherx Biopharma Repurposes Ampligen in Immuno-OncologyBy Nasdaq OMXMay 31, 2017, 4:04 PM UTC
BusinessHemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016By Nasdaq OMXMar 31, 2017, 10:19 PM UTC
BusinessTesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian CancerBy Nasdaq OMXJan 17, 2017, 1:03 PM UTC
BusinessTesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian CancerBy Nasdaq OMXJan 17, 2017, 1:03 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
